Drug Patents Expiring in 2039
1. Drug name - AIRDUO DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11000653
(Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Treatment: NA
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.113MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.232MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
2. Drug name - ANJESO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10881663 | BAUDAX | Method of treating pain in elderly patients with mild renal impairment |
Mar, 2039
(16 years from now) | |
Drugs and Companies using MELOXICAM ingredient
Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 30MG/ML (30MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
3. Drug name - ANNOVERA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632066 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10780047 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10765628 | THERAPEUTICSMD INC | Method of providing birth control |
Feb, 2039
(16 years from now) | |
| US10925882 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10918649 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
| US10940157 | THERAPEUTICSMD INC | System for providing birth control |
Jun, 2039
(16 years from now) | |
Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient
Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception
Dosage: RING;VAGINAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.013MG/24HR;0.15MG/24HR | RING;VAGINAL | Prescription |
4. Drug name - ARMONAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US11000653
(Pediatric) | TEVA PHARM | Inhaler |
Jun, 2039
(16 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH | POWDER;INHALATION | Discontinued |
| 0.113MG/INH | POWDER;INHALATION | Discontinued |
| 0.232MG/INH | POWDER;INHALATION | Discontinued |
| 0.03MG/INH | POWDER;INHALATION | Discontinued |
5. Drug name - BAQSIMI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10765602 | ELI LILLY AND CO | Medication delivery systems and methods |
Sep, 2039
(16 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 3MG | POWDER;NASAL | Prescription |
6. Drug name - BYLVAY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10975046 | ALBIREO | Crystal modifications of odevixibat |
Jun, 2039
(16 years from now) | |
Drugs and Companies using ODEVIXIBAT ingredient
Treatment: NA
Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.2MG | CAPSULE, PELLETS;ORAL | Prescription |
| 0.6MG | CAPSULE, PELLETS;ORAL | Prescription |
| 0.4MG | CAPSULE;ORAL | Prescription |
| 1.2MG | CAPSULE;ORAL | Prescription |
7. Drug name - CAPLYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10695345 | INTRA-CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(16 years from now) | |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
Treatment: Treatment of schizophrenia
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 42MG BASE | CAPSULE;ORAL | Prescription |
8. Drug name - DHIVY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11033521 | AVION PHARMS | Levodopa fractionated dose composition and use |
Mar, 2039
(16 years from now) | |
Drugs and Companies using CARBIDOPA; LEVODOPA ingredient
Treatment: Treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 25MG;100MG | TABLET;ORAL | Prescription |
9. Drug name - ELCYS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10912795 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10905713 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10933089 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10918662 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10653719 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10905714 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10583155 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10478453 | EXELA PHARMA | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 500MG/10ML (50MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
10. Drug name - EPIDIOLEX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11207292 | GW RES LTD | Cannabidiol preparations and its uses |
Apr, 2039
(16 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 100MG/ML | SOLUTION;ORAL | Prescription |
11. Drug name - INGREZZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11026931 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2039
(16 years from now) | |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
| EQ 60MG BASE | CAPSULE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE;ORAL | Prescription |
12. Drug name - KATERZIA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799453 | AZURITY | Amlodipine formulations |
Apr, 2039
(16 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 1MG BASE/ML | SUSPENSION;ORAL | Prescription |
13. Drug name - LYVISPAH
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(16 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Treatment: Method for treating spasticity
Dosage: GRANULES;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/PACKET | GRANULES;ORAL | Prescription |
| 10MG/PACKET | GRANULES;ORAL | Prescription |
| 20MG/PACKET | GRANULES;ORAL | Prescription |
14. Drug name - NOURESS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10905713 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10933089 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10905714 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10653719 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10912795 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10918662 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10583155 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10478453 | BAXTER HLTHCARE CORP | Stable, highly pure L-cysteine compositions for injection and methods of use |
Jan, 2039
(16 years from now) | |
| US10702490 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US10543186 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US10493051 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
| US11045438 | BAXTER HLTHCARE CORP | Cysteine composition and injection |
Mar, 2039
(16 years from now) | |
Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient
Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 500MG/10ML (50MG/ML) | SOLUTION;INTRAVENOUS | Discontinued |
15. Drug name - NURTEC ODT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11083724 | BIOHAVEN IRELAND | Rimegepant for CGRP related disorders |
Mar, 2039
(16 years from now) | |
Drugs and Companies using RIMEGEPANT SULFATE ingredient
Treatment: Acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 75MG BASE | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
16. Drug name - ORLADEYO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 110MG BASE | CAPSULE;ORAL | Prescription |
| EQ 150MG BASE | CAPSULE;ORAL | Prescription |
17. Drug name - OZOBAX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610502 | METACEL PHARMS LLC | Oral baclofen solutions |
Aug, 2039
(16 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Treatment: Treatment of spasticity
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/5ML | SOLUTION;ORAL | Prescription |
18. Drug name - POTASSIUM PHOSPHATES
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10632150 | CMP DEV LLC | Potassium phosphates composition for injection |
Apr, 2039
(16 years from now) | |
Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient
Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
19. Drug name - QVAR REDIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792447 | NORTON WATERFORD | Breath actuated inhaler |
Jan, 2039
(16 years from now) | |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.04MG/INH | AEROSOL, METERED;INHALATION | Prescription |
| 0.08MG/INH | AEROSOL, METERED;INHALATION | Prescription |
20. Drug name - SOTALOL HYDROCHLORIDE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799138 | ALTATHERA PHARMS LLC | Method of administering sotalol IV/switch |
Apr, 2039
(16 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 150MG/10ML (15MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
21. Drug name - TIBSOVO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(16 years from now) | |
Drugs and Companies using IVOSIDENIB ingredient
Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 250MG | TABLET;ORAL | Prescription |
22. Drug name - TRUDHESA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11185497 | IMPEL NEUROPHARMA | Intranasal delivery of dihydroergotamine by precision olfactory device |
Jan, 2039
(16 years from now) | |
Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient
Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| 0.725MG/SPRAY | SPRAY, METERED;NASAL | Prescription |
23. Drug name - UPNEEQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10799481 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(17 years from now) | |
| US10814001 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(17 years from now) | |
| US10898573 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(17 years from now) | |
| US11103482 | RVL PHARMS | Oxymetazoline compositions |
Dec, 2039
(17 years from now) | |
| US10940138 | RVL PHARMS | Compositions and methods for treating ocular disorders |
Dec, 2039
(17 years from now) | |
Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient
Treatment: Method of treating blepharoptosis
Dosage: SOLUTION/DROPS;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 0.1% | SOLUTION/DROPS;OPHTHALMIC | Prescription |
24. Drug name - VUITY
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE INC | Presbyopia treatments |
Apr, 2039
(16 years from now) | |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
| Strength | Dosage | Availability |
|---|---|---|
| 1.25% | SOLUTION;OPHTHALMIC | Prescription |
25. Drug name - XARELTO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10828310 | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jan, 2039
(16 years from now) | |
|
US10828310
(Pediatric) | JANSSEN PHARMS | Reducing the risk of cardiovascular events |
Jul, 2039
(16 years from now) | |
Drugs and Companies using RIVAROXABAN ingredient
Treatment: Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
| 15MG | TABLET;ORAL | Prescription |
| 20MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.